Gene Editing Tool Fights Cancer in Early Study
So far, CRISPR has only been tried in three patients, two with multiple myeloma and one with a sarcoma. All had tried standard treatments, to no avail.
AbstractHematologic malignancies include several lymphoproliferative and myeloproliferative disorders, many of which are frequently encountered in current health care settings. These malignancies frequently affect the gastrointestinal (GI) tract, either by secondary extranodal or extramedullary extension to the GI tract, or as a primary process arising in the GI tract. In fact, the GI tract may represent the most common extranodal site of involvement in many of them, such as lymphoma. Furthermore, in the current era of improved cancer treatment and advanced transplant procedures with increased survival, it has been quite c...
The initial findings from a small clinical trial of patients with multiple myeloma or sarcoma suggest that gene-edited immunotherapy is safe.
AbstractBackgroundNY-ESO-1 and LAGE-1a are antigens expressed in several tumours, including non-small cell lung cancer (NSCLC). Previous clinical trials using autologous T cells directed against NY-ESO-1/LAGE-1a have shown objective responses between 40% and 60% in synovial sarcoma, metastatic melanoma and multiple myeloma. Pembrolizumab (PEM) is a monoclonal antibody that blocks PD-1/PD-L1 interaction and increases anti-tumour activity in anti-tumour T cells. Here, PEM will be used in combination with NY-ESO-1/LAGE-1a T-cell receptor engineered patient T cells (GSK3377794) to potentially improve clinical benefit in this p...
Conditions: Pancreatic Adenocarcinoma; Osteosarcoma; MPNST (Malignant Peripheral Nerve Sheath Tumor); Chondrosarcoma; Soft Tissue Sarcoma; Glioblastoma; Carcinoma of Breast; Lymphoma; Multiple Myeloma; Gall Bladder Cancer Intervention: Drug: DeltaRex-G Sponsor: Aveni Foundation Temporarily not available
Anthracyclines have been in clinical use for decades due to their anti-neoplastic effects in many cancers including breast cancer, leukaemia, lymphoma, sarcoma, lung cancer and multiple myeloma, however the effective use of these agents is limited by the danger of cardiotoxicity . Incidence of cardiotoxicity in patients treated with anthracyclines varies according to cardiotoxicity definition, but has been reported as high as 26% for heart failure and 36% for left ventricular dysfunction [2,3], with the major predicting factor being anthracycline cumulative dose.
Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; S arcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; &n...
Conditions: Malignancy; Non-hodgkin Lymphoma; Multiple Myeloma; Breast Cancer; Ovarian Cancer; Soft Tissue Sarcoma; Squamous Cell Carcinoma; Head and Neck Cancer; DLBCL; Mantle Cell Lymphoma; Follicular Lymphoma; Leiomyosarcoma; Pancreatic Cancer; Sarcom a; CLL Intervention: Drug: CYT-0851 Sponsor: Cyteir Therapeutics, Inc. Not yet recruiting